Indivior Pharmaceuticals, Inc. (INDV) · Oct 6, 2026 · Acquisition
Merger disclosure supplement — Two stockholder complaints and demand letters; October 15 special meetings remain scheduled
Indivior’s merger filing adds proxy disclosures after two Supernus stockholder complaints, but leaves the deal terms and October 15 votes unchanged.
Indivior is trying to accelerate SUBLOCADE-led growth in opioid-use-disorder treatment, while Supernus brings a broader neurology and psychiatry portfolio; the proposed combination is meant to create a more diversified CNS drug company.
The filing adds process risk, not a new transaction: After the definitive proxy was mailed, Supernus received stockholder demand letters and two New York complaints alleging incomplete merger disclosures. The companies deny the claims but are adding disclosures to reduce the chance of litigation delaying the deal. 〔0〕
The deal economics are not being renegotiated: The supplement corrects and expands banker-analysis inputs, including Supernus cash of approximately $372 million, Indivior cash of approximately $249 million, Indivior debt of approximately $500 million, and the $1 billion special dividend.
| Deal-analysis item | Updated disclosure |
|---|---|
| Supernus estimated cash | ~$372 million (Cantor analysis) |
| Supernus estimated debt | $0 (Cantor analysis) |
| Indivior estimated cash | ~$249 million (Cantor analysis) |
| Indivior estimated debt | ~$500 million (Cantor analysis) |
| Special dividend | $1 billion (Cantor analysis) |
| Supernus implied value range | $50.55–$59.50 per share (Cantor analysis) |
| Indivior dividend-adjusted implied value range | $24.20–$43.90 per share (Cantor analysis) |
The immediate milestone is still the shareholder vote: Both companies are scheduled to hold special meetings on October 15, 2026. 〔1〕 The filing does not announce a changed exchange ratio, a revised closing date, or a new deal term; it mainly makes the proxy record more complete while litigation risk remains an added complication.
Bottom line: This is a procedural merger update with a modest negative wrinkle: stockholder litigation creates delay risk, but the transaction’s basic economics and voting timetable remain intact. The direction was already known; the new information is the disclosure dispute and corrected valuation inputs.
Indivior and Supernus stockholder votes, October 15
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!